What is Halozyme Therapeutics Accounts Receivable?
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Halozyme Therapeutics's accounts receivables for the quarter that ended in Mar. 2024 was $191.5 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Halozyme Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 89.22.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Halozyme Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-7.65.
Halozyme Therapeutics Accounts Receivable Historical Data
The historical data trend for Halozyme Therapeutics's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Halozyme Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Halozyme Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Halozyme Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Halozyme Therapeutics Accounts Receivable Related Terms
Thank you for viewing the detailed overview of Halozyme Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Halozyme Therapeutics (Halozyme Therapeutics) Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HALO has been successfully added to your 